Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Family with sequence similarity 83 (FAM83) members play important roles in carcinogenesis and
tumor progression
in several tumor types. However, the mechanism by which cancer cells regulate
FAM83F
still remains unclear. In this study, we found that the FAM84F protein and messenger RNA (mRNA) levels were consistently upregulated in esophageal squamous cell carcinoma (ESCC) tissues, which suggests that a post-transcriptional mechanism may be involved in the regulation of
FAM83F
. Since microRNAs (miRNAs) are powerful post-transcriptional regulators of gene expression, we performed bioinformatic analyses to search for miRNAs that could potentially target
FAM83F
. We identified the specific targeting site of miR-143 in the 3'-untranslated region (3'-UTR) of
FAM83F
and confirmed the inverse correlation between the levels of miR-143 and
FAM83F protein
and mRNA in ESCC tissue samples. By overexpressing or silencing miR-143 in ESCC cells, we experimentally validated that miR-143 directly binds to the 3'-UTR of the
FAM83F
transcript and degrades the
FAM83F
mRNA to regulate
FAM83F
expression. Furthermore, the biological consequences that miR-143 mediated by targeting
FAM83F
were examined using in vitro cell proliferation, apoptosis, migration, and invasion assays. We demonstrate that miR-143 exerted a tumor-suppressing effect by inhibiting the proliferation, migration, and invasion and inducing G1/G0 phase arrest of ESCC cells via the negative regulation of
FAM83F
expression. Taken together, our findings provide important evidence which supports the role of miR-143 as a tumor suppressor in ESCC via the inhibition of
FAM83F
expression.
...
PMID:miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma. 2777 34